Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis

Dosing of most drugs must be adapted in renal insufficiency, making accurate assessment of renal function essential in clinical medicine. Furthermore, even modest impairment of renal function has been recognized as a cardiovascular risk factor. The purpose of this analysis was to identify the role of symmetric dimethylarginine (SDMA), the structural isomer of the cardiovascular risk marker asymmetric dimethylarginine, as an endogenous marker of renal function.Comprehensive searches of Medline and the Cochrane Library from 1970 to February 2006 were performed to identify studies that evaluated the correlation between SDMA and renal function. The search was augmented by scanning references of identified articles and reviews. The correlation coefficients (R) were recorded from each study for the values of 1/SDMA and clearance estimates and for SDMA and creatinine levels. The summary correlation coefficients with 95% confidence intervals (CIs) were pooled using the random-effects method.In 18 studies involving 2136 patients systemic SDMA concentrations correlated highly with inulin clearance R = 0.85 (CI 0.76-0.91, P < 0.0001), as well as with various clearance estimates combined R = 0.77 (CI 0.65-0.85, P < 0.0001) and serum creatinine R = 0.75 (CI 0.46-089, P < 0.0001).SDMA exhibits some properties of a reliable marker of renal function. Future studies have to clarify whether SDMA is indeed suited to improve diagnosis and eventually optimize care of patients.